Answers are grounded in this paper and cite their sources.
Urine is in direct contact with bladder tumors, making it an ideal biofluid for non-invasive biomarker discovery. This study aimed to identify urine-based protein biomarkers for bladder cancer diagnosis and treatment response monitoring. By analyzing transcriptomic data from bladder cancer cell lines with differential sensitivity to chemotherapy and radiotherapy, we identified four secreted proteins associated with treatment resistance: collagen type I alpha 1 chain (COL1A1), microfibrillar-associated protein 5 (MFAP5), dipeptidyl-peptidase 4 (DPP4), and extracellular matrix protein 1 (ECM1). Urinary concentrations were quantified by enzyme-linked immunosorbent assay (ELISA) in 57 bladder cancer patients and 22 cancer-free controls. All four markers were significantly elevated in patients, and a combined four-marker panel outperformed individual markers (area under the curve [AUC] = 0.916, 95% confidence interval [CI] = 0.858–0.975), with discrimination driven primarily by stage T1 or higher disease. In a treatment-monitoring cohort of 13 patients receiving systemic chemotherapy and/or radiotherapy, changes in urinary COL1A1, MFAP5, and ECM1 from baseline were concordant with CT-based response, with COL1A1 showing the highest concordance (92.3%). These exploratory findings suggest that urinary secreted proteins may reflect disease status during treatment. However, their added value over imaging was not assessed, and their utility in surveillance settings warrants future investigation.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: